Harvard Bioscience (HBIO) Restructuring Costs (2010 - 2026)

Harvard Bioscience (HBIO) has reported Restructuring Costs for 11 consecutive years, with $318000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Restructuring Costs rose 960.0% year-over-year to $318000.0 in Q2 2026; TTM through Jun 2026 was $631000.0, a 10.5% decrease from a year earlier, with the FY2022 full-year figure at -$233000.0, changed N/A from the prior year.
• Restructuring Costs was $318000.0 for Q2 2026 at Harvard Bioscience, up from $235000.0 in the prior quarter.
• Over five years, Restructuring Costs peaked at $5.2 million in Q1 2022 and troughed at -$4.9 million in Q2 2022.
• A 4-year average of $107300.0 and a median of $139500.0 in 2024 frame the typical range for Restructuring Costs.
• Across the five-year window, Restructuring Costs plunged 92.42% in 2025 and jumped 960.0% in 2026, its largest moves.
• Over 4 years, Restructuring Costs stood at -$544000.0 in 2022, then soared by 132.9% to $179000.0 in 2024, then tumbled by 73.18% to $48000.0 in 2025, then surged by 562.5% to $318000.0 in 2026.
• The last three Restructuring Costs figures came in at $318000.0 (Q2 2026), $235000.0 (Q1 2026), and $48000.0 (Q3 2025), per Business Quant data.